In the deal Pfizer will market a number of products in Europe:
- Neonatal and Clostridia vaccines for rumniants.
- E coli vaccines for pigs.
- Influenza and tetanus vaccines for horses.
- Rabies vaccines.
- Companion-animal veterinary speciality products.
- Parasiticides and anti-inflammatories.
The acquisition is subject to certain closing conditions, including antitrust approval. Terms of the agreement were not disclosed.
Pfizer Animal Health’s Europe president, Albert Bourla, said the acquisition would enable Pfizer Animal Health Europe to build upon its comprehensive animal health solutions for vets and their clients – farmers and pet owners.
“We look forward to offering veterinarians additional preventative therapies and treatments along with our technical expertise and services to ensure that animals receive the best care possible,” he said.
Pfizer Inc, in the USA, claims to be the world’s largest research-based pharmaceutical company, focused on discovering and developing innovative animal vaccines and prescription medicines.
Pfizer Animal Health division aims to improve the safety, quality and productivity of the world’s food supply by enhancing the health of livestock and poultry.